** Drug developer enGene Holdings' ENGN.O shares rise 7.2% to $6.24
** H.C. Wainwright starts coverage with "buy" rating and PT of $25 — a ~4x upside to Friday's close
** Brokerage says ENGN's lead drug, detalimogene, can be administered safer and simpler than other gene therapies
** ENGN reported in September that the drug had a complete response rate at any time of 71% in patients with high-risk non-muscle invasive bladder cancer
** Brokerage says this is in-line with treatments from CG Oncology CGON.O and Johnson & Johnson JNJ.N
** Complete response rate is the percentage of patients in a clinical trial whose cancer completely disappears after treatment.
** Brokerage says investors should "consider the holistic risk/reward profiles of treatments" rather than focusing solely on the metric
** Expects FDA approval for ENGN's drug by 2027 and sales of $868 mln by 2034
** All ten brokerages rate stock "buy" or higher; median PT is $30 - LSEG
** As of last close, stock has fallen 36.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.